Market cap
$31 Mln
Revenue (TTM)
$35 Mln
P/E Ratio
--
P/B Ratio
18.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -89.87 | -77.60 | -45.80 | -47.66 | -23.44 |
| EBIT | 18.37 | -1.70 | -56.09 | -36.07 | 1.09 |
| Net Profit | 17.17 | -1.30 | -55.23 | 10.09 | 0.12 |
| EPS | 28.20 | 42.73 | -1.42 | 15.28 | 9.35 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -183.36 | -179.31 | -358.88 | -312.25 | -170.33 |
| Net Margin
| -- | -156.45 | -356.89 | -- | -- |
| Return on equity
| -1,071.24 | -662.38 | -- | -2,891.84 | -185.39 |
| Return on Capital
| -199.33 | -137.10 | -- | -373.30 | -112.36 |
| Return on Assets
| -98.86 | -69.60 | -169.68 | -152.35 | -73.38 |
| Debt to Equity (x)
| -- | -- | 0.00 | -1.88 | 1.34 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
-373.30
|
-112.36
|
-112.33
|
-50.50
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
-2,891.84
|
-185.39
|
-136.47
|
-57.37
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-169.68
Lower than Peers by 138.70
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
-169.68
|
-152.35
|
-73.38
|
-70.85
|
-29.94
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-358.88
Lower than Peers by 275.26
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
-358.88
|
-312.25
|
-170.33
|
-67.52
|
-180.85
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-356.89
Lower than Peers by 264.22
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
-356.89
|
-310.81
|
-169.45
|
-146.30
|
-159.26
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
-45.80
Lower than Peers by 99.75
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
-45.80
|
-0.32
|
-0.67
|
0.58
|
0.01
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
-56.09
Lower than Peers by 55.29
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
-56.09
|
-25.45
|
17.27
|
40.88
|
-9.79
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-55.23
Lower than Peers by 47.93
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
-55.23
|
-25.52
|
62.01
|
-34.09
|
-7.84
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
-1.42
Lower than Peers by 16.07
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
-1.42
|
0.22
|
0.68
|
-0.24
|
0.05
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
-1.88
|
1.34
|
0.46
|
0.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
-0.12
|
0.19
|
0.06
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
--
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
0.84
|
1.13
|
1.98
|
2.69
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
--
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
--
|
--
|
--
|
2.69
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
--
|
--
|
--
|
-21.34
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
0.02
Lower than Peers by 19.12
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
0.02
|
26.58
|
7.96
|
2.31
|
4.02
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.48
Higher than Peers by 0.41
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
0.48
|
0.49
|
0.43
|
0.48
|
0.17
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
69.77
|
27.38
|
8.85
|
17.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
--
|
--
|
0.00
|
-1,329.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
718.82
|
599.79
|
310.06
|
485.33
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
--
|
--
|
-301.21
|
-1,797.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
-1.15
|
-2.19
|
-0.37
|
-2.69
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
18.13
Higher than Peers by 12.95
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
18.13
|
-9.94
|
9.42
|
1.16
|
1.75
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-1.00
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
-1.00
|
-1.27
|
-2.28
|
-0.55
|
-1.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
31
Lower than Peers by 115
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
31
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|